Shares of Max Healthcare Institute Ltd. opened higher on Friday, October 17, after Swiss investment bank UBS raised its price target on the stock, describing it as a "super compounder."

UBS increased its price target on Max Healthcare by 15% to ₹1,550 from ₹1,350 earlier. The new target implies a potential upside of around 30% from the stock's closing price on Thursday. The brokerage has also maintained a 'Buy' rating on the stock.

According to UBS, Max Healthcare is well-positioned to deliver both capacity expansion and earnings growth. The brokerage said that a Central Government Health Scheme (CGHS) price increase would provide a meaningful tailwind for the company.

UBS estimates an 18% compound annual growth rate (CAGR) in bed additions between FY25 and FY28, with around 80% of new

See Full Page